These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 2508120)

  • 1. Cooperative action of the prostacyclin analogue taprostene and the fibrinolytic prourokinase (r-scu-PA) in experimental artery thrombosis.
    Groves R; Schneider J; Flohé L
    Prog Clin Biol Res; 1989; 301():603-7. PubMed ID: 2508120
    [No Abstract]   [Full Text] [Related]  

  • 2. Additional myocardial salvage by coadministration of the epoprostenol analog taprostene to recombinant single-chain urokinase-type plasminogen activator in a canine coronary thrombosis model.
    Groves R; Schneider J; Friderichs E; Giertz H; Flohé L
    Arzneimittelforschung; 1989 Apr; 39(4):534-8. PubMed ID: 2665759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic effect on thrombolysis of sequential infusion of tissue-type plasminogen activator (t-PA) single-chain urokinase-type plasminogen activator (scu-PA) and urokinase in the rabbit jugular vein thrombosis model.
    Collen D; Stassen JM; De Cock F
    Thromb Haemost; 1987 Oct; 58(3):943-6. PubMed ID: 3124288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Additive fibrinolysis by recombinant tissue-type plasminogen activator (r-t-PA) and recombinant single-chain urokinase type plasminogen activator (r-scu-PA) in rabbit pulmonary thrombosis.
    Schneider J; Friderichs E; Günzler WA; Flohé L
    Thromb Res; 1989 Oct; 56(1):59-65. PubMed ID: 2512686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potentiation by heparin fragments of thrombolysis induced with human tissue-type plasminogen activator or human single-chain urokinase-type plasminogen activator.
    Stassen JM; Juhan-Vague I; Alessi MC; De Cock F; Collen D
    Thromb Haemost; 1987 Oct; 58(3):947-50. PubMed ID: 2829381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tissue-type plasminogen activator (t-PA) and single chain urokinase-type plasminogen activator (scu-PA): potential for fibrin-specific thrombolytic therapy.
    Collen D
    Prog Hemost Thromb; 1986; 8():1-18. PubMed ID: 3104986
    [No Abstract]   [Full Text] [Related]  

  • 7. Taprostene, a stable prostacyclin analogue, enhances the thrombolytic efficacy of saruplase (recombinant single-chain urokinase-type plasminogen activator) in rabbits with pulmonary embolized thrombi.
    Schneider J
    Prostaglandins; 1991 Jun; 41(6):595-606. PubMed ID: 2052741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibrin-specific thrombolytic agents.
    Collen D
    Schweiz Med Wochenschr; 1987 Nov; 117(46):1791-8. PubMed ID: 3122317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coronary thrombolysis in man with pro-urokinase: improved efficacy with low dose urokinase.
    Kasper W; Meinertz T; Hohnloser S; Engler H; Hasler C; Rössler W; Wolf H; Welzel D; Just H; Gurewich V
    Klin Wochenschr; 1988; 66 Suppl 12():109-14. PubMed ID: 3126340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.
    Collen D; De Cock F; Demarsin E; Lijnen HR; Stump DC
    Thromb Haemost; 1986 Aug; 56(1):35-9. PubMed ID: 3095946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergism of tissue-type plasminogen activator (t-PA) and single-chain urokinase-type plasminogen activator (scu-PA) on clot lysis in vitro and a mechanism for this effect.
    Gurewich V; Pannell R
    Thromb Haemost; 1987 Jun; 57(3):372-3. PubMed ID: 3116707
    [No Abstract]   [Full Text] [Related]  

  • 12. [Development of new thrombolytic substances].
    Zeymer U; Neuhaus KL
    Herz; 1994 Dec; 19(6):314-25. PubMed ID: 7843688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The nature of synergy between tissue-type and single chain urokinase-type plasminogen activators.
    Fry ET; Mack DL; Sobel BE
    Thromb Haemost; 1989 Nov; 62(3):909-16. PubMed ID: 2512679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced myocardial salvage by combined treatment with recombinant single-chain urokinase-type plasminogen activator and recombinant human superoxide dismutase in a canine coronary thrombosis model.
    Fincke U; Schneider J; Friderichs E; Giertz H; Flohé L
    Arzneimittelforschung; 1988 Jan; 38(1):138-42. PubMed ID: 3365272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonpeptide factor Xa inhibitors III: effects of DPC423, an orally-active pyrazole antithrombotic agent, on arterial thrombosis in rabbits.
    Wong PC; Crain EJ; Watson CA; Zaspel AM; Wright MR; Lam PY; Pinto DJ; Wexler RR; Knabb RM
    J Pharmacol Exp Ther; 2002 Dec; 303(3):993-1000. PubMed ID: 12438519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Properties of chimeric (tissue-type/urokinase-type) plasminogen activators obtained by fusion at the plasmin cleavage site.
    Colucci M; Cavallo LG; Agnelli G; Mele A; Bürgi R; Heim J; Semeraro N
    Thromb Haemost; 1993 May; 69(5):466-72. PubMed ID: 8391727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of combined administration of saruplase and single-chain alteplase on coronary recanalization in acute myocardial infarction.
    Tranchesi B; Bellotti G; Chamone DF; Verstraete M
    Am J Cardiol; 1989 Jul; 64(3):229-32. PubMed ID: 2500842
    [No Abstract]   [Full Text] [Related]  

  • 18. Enhanced thrombolysis in plasma and in vivo by single-chain urokinase-type plasminogen activator (scuPA) conjugated to an antifibrin antibody.
    Bode C; Runge M; Eberle T; Freitag M; Kübler W; Haber E
    Trans Assoc Am Physicians; 1989; 102():7-12. PubMed ID: 2517856
    [No Abstract]   [Full Text] [Related]  

  • 19. In vitro analysis of synergistic effects of fibrinolytic agents and prostacyclin analogues.
    Spiecker M; Heinke B; Meyer J; Darius H
    Haemostasis; 1997; 27(4):184-92. PubMed ID: 9483173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effects of potentiation and rapid action in models of venous thrombosis in dogs upon combined administration of the plasminogen tissue activator and urokinase modified by fibrinogen].
    Maksimenko AV; Tishchenko EG; Petrova ML; Golubykh VL
    Biull Eksp Biol Med; 1996 Jan; 121(1):48-51. PubMed ID: 8680005
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.